The Recall Desk

State

Minnesota product recalls

73,833 recalls have nationwide distribution and so reach Minnesota. 7,851 additional recalls listed Minnesota specifically in their distribution scope.

What the numbers show

Total
7,851
Critical
1,137
Severe
2,246
Most recent
2026-11-04

Of the 7,851 recalls naming Minnesota we have scored against our rubric, 1,137 (14%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 2,246 (29%) are Severe.

These figures cover only the 7,851 recalls whose distribution notice names Minnesota specifically. The 73,833 nationwide recalls listed below reach every state, so counting them here would make every state page show the same numbers.

60426–60450 of 81684

  • SevereFDA (Drugs)·D-0965-2015·2015-04-29

    SCA Pharmaceuticals Recalls Droperidol Injection Due to Particulate Presence

    SCA Pharmaceuticals is recalling 421 syringes of Droperidol injection because of the presence of particulate matter. The product was distributed in Indiana, Arkansas, Missouri, and Minnesota.

    Product
    Droperidol injection, 2.5 mg/mL, 5 mg Total Dose, 2 mL Fill Volume per syringe, packaged in 10-count syringes per heat sealed bag, RX only; Compounded for Office Use by SCA Pharmaceuticals, Little Rock, AR (877 ) 550-5059 Bar Code 88888-7720-16
    Category
    Drug
    Distribution
    4 states
  • SevereFDA (Drugs)·D-904-2015·2015-04-29

    Attix Pharmaceuticals Recalls Streptomycin Sulfate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Streptomycin Sulfate API because it was repackaged in a facility with penicillin products without adequate separation, creating a cross-contamination risk.

    Product
    Streptomycin Sulfate or Sulphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-731-2015·2015-04-29

    Attix Pharmaceuticals Recalls Imiquimod Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Imiquimod active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Imiquimod active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-591-2015·2015-04-29

    Attix Pharmaceuticals Recalls Citalopram Hydrobromide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Citalopram Hydrobromide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Citalopram Hydrobromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-617-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dasatinib API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Dasatinib active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Dasatinib active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-542-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bethanechol Chloride Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Bethanechol Chloride active pharmaceutical ingredient due to potential penicillin cross contamination from inadequate facility separation.

    Product
    Bethanechol Chloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-913-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tamoxifen Citrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tamoxifen Citrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Tamoxifen Citrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-853-2015·2015-04-29

    Attix Pharmaceuticals Recalls Pralidoxime Chloride Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Pralidoxime Chloride active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Pralidoxime Chloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-916-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tegaserod Maleate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tegaserod Maleate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Tegaserod Maleate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-721-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hydroxyprogesterone Caproate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hydroxyprogesterone Caproate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Hydroxyprogesterone Caproate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-587-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cinacalcet HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Cinacalcet HCI active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.

    Product
    Cinacalcet HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-952-2015·2015-04-29

    Attix Pharmaceuticals Recalls Venlafaxine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Venlafaxine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Venlafaxine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-947-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ursodiol API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Ursodiol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Ursodiol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-601-2015·2015-04-29

    Attix Pharmaceuticals Recalls Croscarmellose Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Croscarmellose Sodium pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Croscarmellose Sodium pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-583-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cidofovir Anhydrous Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cidofovir Anhydrous active pharmaceutical ingredient due to a risk of penicillin cross-contamination during repackaging.

    Product
    Cidofovir Anhydrous active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-746-2015·2015-04-29

    Attix Pharmaceuticals Recalls Labetalol HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Labetalol HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Labetalol HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-772-2015·2015-04-29

    Attix Pharmaceuticals Recalls Mebendazole Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Mebendazole active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Mebendazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-895-2015·2015-04-29

    Simvastatin API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Simvastatin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Simvastatin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-795-2015·2015-04-29

    Mevastatin API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Mevastatin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Mevastatin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-735-2015·2015-04-29

    Attix Pharmaceuticals Recalls Iron Sucrose API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Iron Sucrose and Ferric Hydroxide Sucrose Complex active pharmaceutical ingredients due to potential penicillin cross-contamination during repackaging.

    Product
    Iron Sucrose or Ferric Hydroxide Sucrose Complex active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-627-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dexrazoxane Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Dexrazoxane active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Dexrazoxane active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-622-2015·2015-04-29

    Attix Pharmaceuticals Recalls Desoximetasone Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Desoximetasone active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Desoximetasone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-882-2015·2015-04-29

    Attix Pharmaceuticals Recalls Rivaroxaban API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Rivaroxaban active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Rivaroxaban active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-937-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tramadol HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tramadol HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Tramadol HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide